ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease.

Polycystic kidney disease (PKD) is a common genetic disorder leading to cyst formation in the kidneys and other organs that ultimately results in kidney failure and death. Currently, there is no therapy for slowing down or stopping the progression of PKD. In this study, we identified the disintegrin metalloenzyme 17 (ADAM17) as a key regulator of cell proliferation in kidney tissues of conditional knockout Ift88(-/-) mice and collecting duct epithelial cells from Ift88°(rpk) mice, animal models of autosomal recessive polycystic kidney disease (ARPKD). Using Western blotting, an enzyme activity assay, and a growth factor-shedding assay in the presence or absence of the specific ADAM17 inhibitor TMI-005, we show that increased expression and activation of ADAM17 in the cystic kidney and in collecting duct epithelial cells originating from the Ift88°(rpk) mice (designated as PKD cells) lead to constitutive shedding of several growth factors, including heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, and transforming growth factor-α (TGF-α). Increased growth factor shedding induces activation of the EGFR/MAPK/ERK pathway and maintains higher cell proliferation rate in PKD cells compared with control cells. PKD cells also displayed increased lactate formation and extracellular acidification indicative of aerobic glycolysis (Warburg effect), which was blocked by ADAM17 inhibition. We propose that ADAM17 is a key promoter of cellular proliferation in PKD cells by activating the EGFR/ERK axis and a proproliferative glycolytic phenotype.

[1]  S. Asuthkar,et al.  Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. , 2013, Cancer research.

[2]  P. Komlósi,et al.  TRPP2 and TRPV4 Form an EGF-Activated Calcium Permeable Channel at the Apical Membrane of Renal Collecting Duct Cells , 2013, PloS one.

[3]  B. Cho,et al.  Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation , 2013, Molecular Cancer Therapeutics.

[4]  C. Taylor,et al.  ABT-263 Enhances Sensitivity to Metformin and 2-Deoxyglucose in Pediatric Glioma by Promoting Apoptotic Cell Death , 2013, PloS one.

[5]  J. Schlöndorff,et al.  Gain-of-function Mutations in Transient Receptor Potential C6 (TRPC6) Activate Extracellular Signal-regulated Kinases 1/2 (ERK1/2)* , 2013, The Journal of Biological Chemistry.

[6]  I. Clay,et al.  Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling , 2013, Proceedings of the National Academy of Sciences.

[7]  K. Horiuchi,et al.  Systemic Overexpression of TNFα-converting Enzyme Does Not Lead to Enhanced Shedding Activity In Vivo , 2013, PloS one.

[8]  Eiji Higashihara,et al.  Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.

[9]  H. Lo,et al.  Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. , 2012, Cancer letters.

[10]  B. Siroky,et al.  Collecting duct cells that lack normal cilia have mislocalized vasopressin-2 receptors. , 2012, American journal of physiology. Renal physiology.

[11]  S. Higashiyama,et al.  A Disintegrin and Metalloenzyme (ADAM) 17 Activation Is Regulated by α5β1 Integrin in Kidney Mesangial Cells , 2012, PloS one.

[12]  L. Luttrell,et al.  Bradykinin Decreases Podocyte Permeability through ADAM17-Dependent Epidermal Growth Factor Receptor Activation and Zonula Occludens-1 Rearrangement , 2010, Journal of Pharmacology and Experimental Therapeutics.

[13]  S. Hoffman,et al.  ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. , 2009, Biochemical and biophysical research communications.

[14]  B. Magenheimer,et al.  A tumor necrosis factor-α–mediated pathway promoting autosomal dominant polycystic kidney disease , 2008, Nature Medicine.

[15]  R. Kesterson,et al.  Disruption of Intraflagellar Transport in Adult Mice Leads to Obesity and Slow-Onset Cystic Kidney Disease , 2007, Current Biology.

[16]  L. Luttrell,et al.  5-HT2A Receptor Induces ERK Phosphorylation and Proliferation through ADAM-17 Tumor Necrosis Factor-α-converting Enzyme (TACE) Activation and Heparin-bound Epidermal Growth Factor-like Growth Factor (HB-EGF) Shedding in Mesangial Cells* , 2006, Journal of Biological Chemistry.

[17]  N. Murcia,et al.  Transforming Growth Factor Alpha (TGF-α) and Other Targets of Tumor Necrosis Factor-Alpha Converting Enzyme (TACE) in Murine Polycystic Kidney Disease , 2005, Pediatric Research.

[18]  E. Avner,et al.  EGF-related growth factors in the pathogenesis of murine ARPKD. , 2004, Kidney international.

[19]  C. Bugg,et al.  Polaris, a protein disrupted in orpk mutant mice, is required for assembly of renal cilium. , 2002, American journal of physiology. Renal physiology.

[20]  E. Avner,et al.  A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. , 2001, Kidney international.

[21]  B. Yoder,et al.  Polaris, a protein involved in left-right axis patterning, localizes to basal bodies and cilia. , 2001, Molecular biology of the cell.

[22]  P. Wilson,et al.  Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. , 1995, The American journal of physiology.

[23]  E. Avner,et al.  Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. , 1995, Kidney international.

[24]  J. Stockman,et al.  Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease , 2012 .